These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 34745146)
41. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing. Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862 [TBL] [Abstract][Full Text] [Related]
42. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Crowley SJ; Bruck PT; Bhuiyan MA; Mitchell-Gears A; Walsh MJ; Zhangxu K; Ali LR; Jeong HJ; Ingram JR; Knipe DM; Ploegh HL; Dougan M; Dougan SK Open Biol; 2020 Feb; 10(2):190235. PubMed ID: 32019478 [TBL] [Abstract][Full Text] [Related]
43. Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development. Kovjazin R; Volovitz I; Daon Y; Vider-Shalit T; Azran R; Tsaban L; Carmon L; Louzoun Y Mol Immunol; 2011 Apr; 48(8):1009-18. PubMed ID: 21316766 [TBL] [Abstract][Full Text] [Related]
44. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8 Khong H; Volmari A; Sharma M; Dai Z; Imo CS; Hailemichael Y; Singh M; Moore DT; Xiao Z; Huang XF; Horvath TD; Hawke DH; Overwijk WW J Immunol; 2018 May; 200(10):3464-3474. PubMed ID: 29643190 [TBL] [Abstract][Full Text] [Related]
45. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy. Chhabra A Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670 [TBL] [Abstract][Full Text] [Related]
46. The Antitumor Effects of Vaccine-Activated CD8 Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693 [TBL] [Abstract][Full Text] [Related]
47. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
48. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523 [TBL] [Abstract][Full Text] [Related]
49. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742 [TBL] [Abstract][Full Text] [Related]
55. Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. Jalali SA; Parmiani G Recent Pat Biotechnol; 2011 Aug; 5(2):108-17. PubMed ID: 21707528 [TBL] [Abstract][Full Text] [Related]
56. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles. Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663 [TBL] [Abstract][Full Text] [Related]
57. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes. Duong MN; Erdes E; Hebeisen M; Rufer N J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351 [TBL] [Abstract][Full Text] [Related]
58. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. Watson AM; Mylin LM; Thompson MM; Schell TD J Immunol; 2012 Dec; 189(12):5549-60. PubMed ID: 23175697 [TBL] [Abstract][Full Text] [Related]
60. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Dolan BP; Gibbs KD; Ostrand-Rosenberg S J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]